Zuellig Pharma and Organon Partner to Expand Access to Women’s Health Solutions in Myanmar

Yangon, Myanmar, 1st August 2025 – Zuellig Pharma, a leading healthcare solutions company in Asia, has announced a strategic partnership with Organon, a global healthcare company dedicated to improving women’s health.

Through the partnership, Zuellig Pharma and Organon aim to expand access to leading women’s health products via multiple healthcare channels across the market. This collaboration underscores a shared commitment to advancing women’s health outcomes in Myanmar, including addressing unintended pregnancies and improving access to contraception.

Myanmar faces considerable reproductive health challenges, with approximately 1,510,000 pregnancies recorded annually between 2015 and 2019, of which 527,000—nearly one-third—were unintended.¹ This underscores a significant gap in access to family planning and reproductive health resources, as planned pregnancies lead to better health outcomes for mothers and children.

Addressing this issue requires empowering women with the information and support they need to make informed decisions about contraception that align with their priorities, preferences, and lifestyles, as well as choosing the right time to have a child. Unintended pregnancies pose a critical public health challenge, burdening society with financial and social costs, making it essential to improve access to accurate information and resources for informed decision-making.

To address these pressing issues, Zuellig Pharma has been granted the commercialization and distribution rights for Organon’s flagship oral contraceptive solution. Since its introduction to the Myanmar market in May 2025, Organon’s products have been made available nationwide through various healthcare channels, including retail and wholesale pharmacies, modern trade and chain pharmacies, hospital clinics, and medical cabinets.

“At Organon, we are dedicated to addressing the unique health needs of women, which includes improving access to essential reproductive care. We are proud to partner with Zuellig Pharma to ensure broad access to quality contraception in Myanmar. Through these efforts, we aim to empower women in Myanmar to make informed decisions about their reproductive health and build the families they desire,” said Andreas Daugaard Jørgensen, Managing Director of Organon Asia Pacific.

“Central to this is ensuring access to vital health information through Zuellig Pharma’s innovative maternal and neonatal health apps. Organon has contributed by providing educational articles on key topics like postpartum family planning, ensuring critical information reaches those who need it most,” Andreas concluded.

“As a trusted partner across Asia, Zuellig Pharma is pleased to support Organon in advancing critical health outcomes for women in Myanmar. This partnership underscores our shared commitment to expanding access to innovative healthcare solutions and driving long-term impact for women’s health in the region,” said Robert Kruit, Executive Vice President of Corporate Strategy and Business Development for Zuellig Pharma.

Beyond the commercialization of Organon’s women’s reproductive portfolio, this partnership signals a long-term ambition to improve health outcomes for the general population by bringing more specialty therapeutic medicines to Myanmar, as well as ongoing healthcare education and awareness programs.

Reinforcing this commitment, Zuellig Pharma organized a medical symposium following the signing ceremony for the partnership, titled “Unintended Pregnancy: The Preventable Pandemic.” This session highlighted current practices, gaps, and opportunities in family planning across Myanmar. By addressing these challenges, both companies aim to support local healthcare systems through education and improved access.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

For more information, visit: https://www.zuelligpharma.com/

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn

References:

1. Guttmacher Institute. Myanmar country profile, 2022. https://www.guttmacher.org/regions/asia/myanmar